India's Peptide API Race Heats Up as HRV Pharma Commits 150 Crore

India’s peptide API race heats up as HRV Pharma commits Rs 150 crore to secure critical capacity in synthetic peptides.

The Hyderabad-based company moves decisively into two of the most supply-constrained and high-value segments of the global pharmaceutical supply chain.

Rising demand for complex peptides and specialized oncology molecules creates fierce competition among Indian players that can deliver reliable, regulated-market supply.

HRV’s latest investment signals its intent to lock in manufacturing access while preserving the capital-efficient, asset-light model that has defined its growth since 2016.

HRV deploys capital across two strategic platforms

HRV Pharma will channel the Rs 150 crore commitments into two distinct programs.

• Up to Rs 40-50 crore will fund a dedicated custom peptide manufacturing capacity through a strategic capacity-underwriting arrangement with a partner facility.
• Nearly Rs 100 crore will support a joint venture focused on high-potency oncology APIs and specialized molecules.

The peptide capacity will operate under current good manufacturing practice standards and will become ready within six to eight months. HRV will retain full ownership of regulatory assets, product intellectual property, and global commercialization rights.

The company targets commercial-stage and new-to-generic synthetic peptides across multiple therapies for regulated markets, including the United States and Europe, a segment that exceeds USD 2 billion in estimated size.

Also Read: Why Peptides and Complex Generics Will Define India Pharma's Future

Oncology JV aims for 20-30 high-potency molecules

The joint venture will begin with research and development, product development and regulatory filings before it adds dedicated commercial-scale capacity. Management plans to develop 20-30 oncology and high-potency APIs in phases. HRV will keep control over product selection, regulatory filings, intellectual property and global commercialization, while the manufacturing infrastructure remains with the partner.

Leadership view and company background

Hari Kiran Chereddi, founder, managing director and CEO of HRV Pharma, stated that the investments secure critical capacities in peptides and high-potency APIs while they preserve the flexibility and capital efficiency of the company’s operating model. He noted that the firm focuses on areas where the industry requires specialized capabilities.

Founded in 2016, HRV Pharma operates as India’s first virtual pharma company. It relies on proprietary API drug master files, co-owned finished dosage forms and a network of more than 50 USFDA- and EU-GMP-certified manufacturing partners. The company currently sells products in over 55 countries and serves more than 150 corporations worldwide.

With locking in specialized capacity without heavy capital expenditure on owned plants, HRV positions itself to capture a larger share of the fast-growing peptide and oncology API markets. The dual investment sharpens competition in India’s complex API landscape and underscores the strategic value of flexible, partner-driven manufacturing models.